Table 1.
Descriptive Characteristics of Prostate Cancer Patients in the PROGRESS Cohort
| Characteristic | No. = 957 | % |
|---|---|---|
| Age at diagnosis, years | ||
| Mean | 64.5 | |
| Range | 40.0–87.0 | |
| Follow-up time, years | ||
| Mean | 12.73 | |
| Range | 0.28–32.6 | |
| Prostate cancer-specific death | ||
| No1 | 782 | 81.7 |
| Yes | 98 | 10.2 |
| Unknown2 | 77 | 8.0 |
| Age at death, years | ||
| Mean | 80.5 | |
| Range | 54.0–99.0 | |
| Stage at diagnosis | ||
| Local | 623 | 65.1 |
| Regional | 240 | 25.1 |
| Distant | 27 | 2.8 |
| Missing | 67 | 7.0 |
| Gleason score at diagnosis | ||
| ≤ 6 | 561 | 58.6 |
| 7 (3+4) | 159 | 16.6 |
| 7 (4+3) | 45 | 4.7 |
| 8–10 | 80 | 8.4 |
| Missing | 112 | 11.7 |
| Diagnostic PSA level, ng/mL | ||
| < 4.0 | 77 | 8.0 |
| 4–9.9 | 360 | 37.6 |
| 10–19.9 | 157 | 16.4 |
| ≥ 20 | 130 | 13.6 |
| Missing | 233 | 24.3 |
| Primary therapy | ||
| Radical prostatectomy | 501 | 52.4 |
| Radiation therapy | 256 | 26.8 |
| Androgen deprivation | 75 | 7.8 |
| Active surveillance | 21 | 2.2 |
| Other | 18 | 1.9 |
| Missing | 86 | 9.0 |
1
Includes men who died of other causes (n=258) or were alive at last follow-up (n=524).
2
Includes men who died but underlying cause of death is unknown.